Novartis muscle wasting drug gets `breakthrough` status
Zurich: Novartis said on Tuesday U.S. regulators have granted breakthrough therapy status for its investigational compound bimagrumab for the potential treatment of patients with sporadic inclusion body myositis (sIBM).
The U.S. Food and Drug Administration (FDA) created the "breakthrough therapy" designation earlier this year for medicines deemed likely to demonstrate "substantial improvement" over existing drugs.
sIBM is a rare yet potentially life-threatening muscle-wasting condition. Patients suffering from the disease can gradually lose the ability to walk. There are currently no approved treatments, according to Novartis.
Bimagrumab was developed by Novartis in collaboration with Morphosys. The drug works by stimulating muscle growth by blocking from inhibitory molecules.
More from India
More from World
More from Sports
More from Entertaiment
- Assam Board (seba.net.in & resultsassam.nic.in): SEBA HSLC / AHM class 10th Results 2015 to be announced today
- Was asked to call Sunanda Pushkar’s death `natural`: AIIMS doctor
- Maggi row: Delhi registers case against Nestle, Kerala withdraws stock from govt stores
- Rahul Gandhi hails BR Ambedkar, takes potshot at Modi-led NDA govt over IIT Madras row
- From being the ‘Dabangg’ girl to ‘Akira’ - Sonakshi Sinha’s journey so far